Financial Performance & Growth - Repligen's revenue grew from $270 million in 2019 to $634 million in 2024[11], representing a 19% 5-year revenue Compound Annual Growth Rate (CAGR)[11] - The company projects revenue between $695 million and $720 million for 2025, indicating a reported growth of 95% - 135%[92] - Adjusted EPS is projected to be $163 - $172 for 2025[92], compared to $158 in 2024[31, 110] - First quarter 2025 revenue was $169 million[88], including $10 million from the 908 Devices acquisition[63], with organic non-COVID growth at 14%[91] Market & Strategy - The biopharma market is estimated at ~$250 billion in 2024[21] - The company estimates its Total Addressable Market (TAM) has increased by 3x from 2020 to 2024[35] - New modalities represent ~18% of 2024 revenue[13, 54] and are growing at >20% year-over-year[16, 91] - The company has a diversified customer base, with the largest customer representing ~6% of FY-24 revenues[56] Acquisitions & Portfolio - Repligen acquired 908 Devices' bioprocessing product portfolio for $70 million in cash[63] - The company has completed 15 acquisitions between 2014 and 2025[11, 41] - The company estimates that ~2% of 1Q25 revenue is from China[101]